Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

Author(s):
Weinblatt, M.E.; Fleischmann, R.; Huizinga, T.W.J. (0000-0001-7033-7520); Emery, P.; Pope, J.; Massarotti, E.M.; Vollenhoven, R.F. van; Wollenhaupt, J.; Bingham, C.O.; Duncan, B.; Goel, N.; Davies, O.R.; Dougados, M.
Published
2012
Publication type
Article / Letter to editor
rheumatoid arthritisbiologicalstumour necrosis factor
Date issued
2012-12-31
Language
English
Is part of
Rheumatology (2012), Vol. 51, no. 12, p. 2204-2214
hdl
1887/97617
doi
10.1093/rheumatology/kes150